DE Burlo Group Inc. Decreases Stake in Eli Lilly and Company (NYSE:LLY)
by Jessica Moore · The Cerbat GemDE Burlo Group Inc. decreased its holdings in Eli Lilly and Company (NYSE:LLY – Free Report) by 41.3% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 23,938 shares of the company’s stock after selling 16,863 shares during the quarter. Eli Lilly and Company accounts for approximately 2.5% of DE Burlo Group Inc.’s investment portfolio, making the stock its 17th largest holding. DE Burlo Group Inc.’s holdings in Eli Lilly and Company were worth $18,480,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Principal Financial Group Inc. lifted its holdings in shares of Eli Lilly and Company by 5.3% during the 3rd quarter. Principal Financial Group Inc. now owns 1,208,545 shares of the company’s stock valued at $1,070,698,000 after acquiring an additional 60,306 shares in the last quarter. Invst LLC lifted its stake in shares of Eli Lilly and Company by 3.5% during the third quarter. Invst LLC now owns 5,552 shares of the company’s stock worth $4,918,000 after purchasing an additional 189 shares in the last quarter. McIlrath & Eck LLC lifted its stake in shares of Eli Lilly and Company by 3.4% during the third quarter. McIlrath & Eck LLC now owns 481 shares of the company’s stock worth $426,000 after purchasing an additional 16 shares in the last quarter. Virtu Financial LLC boosted its position in shares of Eli Lilly and Company by 111.7% in the third quarter. Virtu Financial LLC now owns 6,531 shares of the company’s stock worth $5,786,000 after buying an additional 3,446 shares during the period. Finally, SOA Wealth Advisors LLC. grew its stake in shares of Eli Lilly and Company by 2.4% in the third quarter. SOA Wealth Advisors LLC. now owns 864 shares of the company’s stock valued at $766,000 after buying an additional 20 shares in the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.
Eli Lilly and Company Trading Up 2.9 %
Eli Lilly and Company stock opened at $884.94 on Friday. The firm’s 50-day moving average is $827.69 and its 200-day moving average is $818.61. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. Eli Lilly and Company has a 1 year low of $677.09 and a 1 year high of $972.53. The company has a market cap of $839.07 billion, a P/E ratio of 75.57, a PEG ratio of 1.40 and a beta of 0.51.
Eli Lilly and Company (NYSE:LLY – Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. On average, equities analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.
Insider Buying and Selling
In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total value of $818,240.00. Following the sale, the chief accounting officer now directly owns 5,840 shares of the company’s stock, valued at $4,778,521.60. This trade represents a 14.62 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 0.13% of the company’s stock.
Wall Street Analyst Weigh In
LLY has been the subject of a number of analyst reports. Cantor Fitzgerald started coverage on Eli Lilly and Company in a report on Tuesday. They issued an “overweight” rating and a $975.00 price target for the company. StockNews.com upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Friday, February 7th. The Goldman Sachs Group raised shares of Eli Lilly and Company from a “neutral” rating to a “buy” rating and dropped their price target for the stock from $892.00 to $888.00 in a research note on Tuesday, April 8th. Morgan Stanley decreased their price objective on shares of Eli Lilly and Company from $1,146.00 to $1,124.00 and set an “overweight” rating for the company in a research report on Wednesday, April 9th. Finally, Truist Financial lifted their target price on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a “buy” rating in a research report on Monday, February 3rd. Two equities research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. According to MarketBeat.com, Eli Lilly and Company has a consensus rating of “Moderate Buy” and a consensus price target of $1,017.00.
Eli Lilly and Company Profile
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Recommended Stories
- Five stocks we like better than Eli Lilly and Company
- What does consumer price index measure?
- Short Sellers Gave Up on These 3 Names Recently
- Pros And Cons Of Monthly Dividend Stocks
- 3 Boring Stocks Outperforming the Market This Year
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).